Literature DB >> 2569974

Pharmacology of the benzodiazepine receptor.

W E Haefely1.   

Abstract

The benzodiazepine receptor (BZR) is an intrinsic allosteric modulatory site of the GABAA-receptor-chloride channel complex of neuronal membranes mediating the main action of the major inhibitory neurotransmitter GABA. The BZR is unique in recognizing three classes of ligands, two of them producing opposite modulatory effects on the GABAA receptor function in an allosteric fashion (agonists and inverse agonists) and the third acting as antagonists of the two others. Agonists and partial agonists of the BZR (belonging to various chemical classes) have therapeutic applications as broad-spectrum tranquilizers and specific anxiolytics- anticonvulsants, respectively. The BZR antagonist flumazenil, recently introduced in therapy, increases the versatility of agonists in therapy and greatly simplifies the treatment of agonist overdosing. Inverse agonists are interesting probes to analyse the biological basis of anxiety-related emotional disorders.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569974     DOI: 10.1007/BF00449811

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  17 in total

1.  GABAergic modulation of benzodiazepine binding site sensitivity.

Authors:  J F Tallman; J W Thomas; D W Gallager
Journal:  Nature       Date:  1978-07-27       Impact factor: 49.962

2.  Benzodiazepine receptors in rat brain.

Authors:  R F Squires; C Brastrup
Journal:  Nature       Date:  1977-04-21       Impact factor: 49.962

Review 3.  Evidence for involvement of GABA in the action of benzodiazepines: studies on rat cerebellum.

Authors:  E Costa; A Guidotti; C C Mao
Journal:  Adv Biochem Psychopharmacol       Date:  1975

4.  Partial agonists of the benzodiazepine receptor: from animal data to results in patients.

Authors:  W Haefely
Journal:  Adv Biochem Psychopharmacol       Date:  1988

5.  Ro 16-6028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor.

Authors:  J R Martin; L Pieri; E P Bonetti; R Schaffner; W P Burkard; R Cumin; W E Haefely
Journal:  Pharmacopsychiatry       Date:  1988-11       Impact factor: 5.788

6.  Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography.

Authors:  Y Samson; P Hantraye; J C Baron; F Soussaline; D Comar; M Mazière
Journal:  Eur J Pharmacol       Date:  1985-04-02       Impact factor: 4.432

7.  Co-localization of GABA receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies.

Authors:  P Schoch; J G Richards; P Häring; B Takacs; C Stähli; T Staehelin; W Haefely; H Möhler
Journal:  Nature       Date:  1985 Mar 14-20       Impact factor: 49.962

Review 8.  The story of flumazenil.

Authors:  W Haefely; W Hunkeler
Journal:  Eur J Anaesthesiol Suppl       Date:  1988

9.  A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, beta-carbolines, and phenobarbitone.

Authors:  P Polc; E P Bonetti; R Schaffner; W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

10.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

View more
  12 in total

Review 1.  Allosteric modulation of ATP-gated P2X receptor channels.

Authors:  Claudio Coddou; Stanko S Stojilkovic; J Pablo Huidobro-Toro
Journal:  Rev Neurosci       Date:  2011-03-16       Impact factor: 4.353

2.  Isolation and characterization of endogenous modulators for GABA system.

Authors:  M Yarom; J Bao; X W Tang; E Wu; Y H Lee; W H Tsai; J Y Wu
Journal:  Neurochem Res       Date:  1992-01       Impact factor: 3.996

Review 3.  Dealing with sadness, madness and hostility. New psychotropic drug remedies for the future.

Authors:  A J Loonen
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 4.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 5.  GABAA receptor: Positive and negative allosteric modulators.

Authors:  Richard W Olsen
Journal:  Neuropharmacology       Date:  2018-01-31       Impact factor: 5.250

Review 6.  A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose.

Authors:  A A Weinbroum; R Flaishon; P Sorkine; O Szold; V Rudick
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

7.  Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.

Authors:  J W Mandema; M T Kuck; M Danhof
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

Review 8.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

9.  RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.

Authors:  Theresa M Ballard; Frédéric Knoflach; Eric Prinssen; Edilio Borroni; Jeffrey A Vivian; Jennifer Basile; Rodolfo Gasser; Jean-Luc Moreau; Joseph G Wettstein; Bernd Buettelmann; Henner Knust; Andrew W Thomas; Gerhard Trube; Maria-Clemencia Hernandez
Journal:  Psychopharmacology (Berl)       Date:  2008-10-21       Impact factor: 4.530

10.  The essential oil from Tagetes minuta L. modulates the binding of [3H]flunitrazepam to crude membranes from chick brain.

Authors:  D A García; M A Perillo; J A Zygadlo; I D Martijena
Journal:  Lipids       Date:  1995-12       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.